A panel asks: "Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?"
At the recently held National Comprehensive Care Network (NCCN) annual conference, Clifford Goodman, PhD, The Lewin Group, moderated a diverse panel of distinguished guests that included, Christian G. Downs, Executive Director, Association of Community Cancer Centers; Liz Fowler, VP, Global Health Policy at Johnson & Johnson; Michael Kolodziej, MD, National Medical Director, Aetna; Lee H. Newcomer, MD, MHA, UnitedHealthcare; Mohammed S. Ogaily, Medical Director for the Oakwood Center, Hematology-Oncology, Detroit, MI; W. Thomas Purcell, MD, Executive Director at University of Colorado Cancer Center; John C. Winkelmann, MD, Oncology Hematology Care, Inc. based in Cincinnati OH, and Councillor, American Society of Hematology. The symposium was titled, “Affordable Care Act: Where Are We Now?” and the panel discussed how in particular the Affordable Care Act (ACA) and reform in the United States is affecting cancer care.
One of the first questions that were asked of the panel was: “Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?”
Read the full story here: http://bit.ly/1lF2CAu
Source: OBR Green
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
2 Commerce Drive
Cranbury, NJ 08512